Suven Pharma Share Price
Suven Pharmaceuticals Ltd.
Performance of Suven Pharma Shares 
Open Price
Prev. Close
Volume
Value
About Suven Pharma
Founded on November 6th, 2018, Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company that provides contract research and manufacturing services for major pharmaceutical, biotechnology, and chemical companies around the world, specializing in the development and production of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals, and Formulated Drugs.
On March 9, 2019, SPL formed a Special Purpose Vehicle (SPV) called Suven Pharma Inc. in the State of Delaware as a wholly owned subsidiary (WOS) to pursue possibilities in the pharmaceutical industry.
In line with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT Hyderabad Bench, during 2019-20, Suven Life Sciences Ltd. (SLSL) transferred the CRAMS business undertaking to the Company, which is now integrated with the Contract Development and Manufacturing Operations (CDMO) business model of the Company. By the approved Scheme, the Company issued and allotted one (1) fully paid-up equity share of SPL with a face value of Re 1/- (Rupee One only) each to each shareholder of the Demerged Company (SLSL) as of the Record Date (i.e., 22nd January 2020), resulting in an equal shareholding of SLSL in the Company.
As of March 9, 2020, the Company's stock is officially traded on the stock market. One new equity share of the Company valued at Re 1 for every existing equity share of the Company valued at Re 1 was discussed, authorized, and recommended by the Board of Directors at its meeting on August 17, 2020.
Their capital expenditure budget is a whopping Rs 320 billion. In 2019-2020, Suven allocated a total of Rs 120 crore. In 2020-21, the remaining funds will be put to use. In 2019-2020, the Company, via its wholly owned subsidiary Suven Pharma Inc. USA, invested USD35 million in Rising Pharma Holdings Inc. USA.
As per the decisions taken by the Board of the Company and of the Demerged Company, i.e., Suven Life Sciences Ltd by the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench, Suven Pharma Inc. in the United States was initially formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period and is now integrated with CDMO business of the Company.
Thus, in the fiscal year 2019-2020, the business acquired 100% of the shares of Suven Pharma Inc. in the United States. To date (31 March 2020), the parent company has a single subsidiary and one associate company.
As of March 31, 2020, 11 ANDAs had been submitted by the corporation; approval had been granted for just 3. The Bonus Shares were issued in a 1:1 ratio at the Board Meeting on September 29, 2020. Shares rose from 127282478 to 254564956 as a result. Do you want to know about the Suven Pharmaceuticals Shares? Click Here to know about today’s Suven Pharmaceuticals Share Price.
On March 9, 2019, SPL formed a Special Purpose Vehicle (SPV) called Suven Pharma Inc. in the State of Delaware as a wholly owned subsidiary (WOS) to pursue possibilities in the pharmaceutical industry.
In line with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT Hyderabad Bench, during 2019-20, Suven Life Sciences Ltd. (SLSL) transferred the CRAMS business undertaking to the Company, which is now integrated with the Contract Development and Manufacturing Operations (CDMO) business model of the Company. By the approved Scheme, the Company issued and allotted one (1) fully paid-up equity share of SPL with a face value of Re 1/- (Rupee One only) each to each shareholder of the Demerged Company (SLSL) as of the Record Date (i.e., 22nd January 2020), resulting in an equal shareholding of SLSL in the Company.
As of March 9, 2020, the Company's stock is officially traded on the stock market. One new equity share of the Company valued at Re 1 for every existing equity share of the Company valued at Re 1 was discussed, authorized, and recommended by the Board of Directors at its meeting on August 17, 2020.
Their capital expenditure budget is a whopping Rs 320 billion. In 2019-2020, Suven allocated a total of Rs 120 crore. In 2020-21, the remaining funds will be put to use. In 2019-2020, the Company, via its wholly owned subsidiary Suven Pharma Inc. USA, invested USD35 million in Rising Pharma Holdings Inc. USA.
As per the decisions taken by the Board of the Company and of the Demerged Company, i.e., Suven Life Sciences Ltd by the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench, Suven Pharma Inc. in the United States was initially formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period and is now integrated with CDMO business of the Company.
Thus, in the fiscal year 2019-2020, the business acquired 100% of the shares of Suven Pharma Inc. in the United States. To date (31 March 2020), the parent company has a single subsidiary and one associate company.
As of March 31, 2020, 11 ANDAs had been submitted by the corporation; approval had been granted for just 3. The Bonus Shares were issued in a 1:1 ratio at the Board Meeting on September 29, 2020. Shares rose from 127282478 to 254564956 as a result. Do you want to know about the Suven Pharmaceuticals Shares? Click Here to know about today’s Suven Pharmaceuticals Share Price.
Fundamentals of Suven Pharma Shares
Market Cap |
P/E Ratio |
P/B Ratio |
Industry P/E |
|---|---|---|---|
Rs. 11996.37 Cr |
28.19 |
10.34 |
63.53 |
ROE |
EPS (TTM) |
Dividend Yield |
Book Value |
|---|---|---|---|
43.17 % |
21.92 |
0.81 % |
63.60 |
Similar Stocks
FAQ’s
How to buy Suven Pharmaceuticals Ltd. shares?
All you have to do to buy Suven Pharmaceuticals Ltd. share is download Nuuu app, create a demat account, and get your KYC documents verified online.
Can I buy Suven Pharmaceuticals Ltd. shares?
Yes you can buy Suven Pharmaceuticals Ltd. shares, all you need is to have a verified demat account with Nuuu. And enjoy benefits like free brokerage credits and more.
What is the Market Cap of Suven Pharmaceuticals Ltd. shares?
As of 31 Mar`23 the Market Cap of Suven Pharmaceuticals Ltd. is 11996.37.
What is the PE and PB ratio of Suven Pharmaceuticals Ltd. stock?
As of 31 Mar`23 the PE is 28.19 and PB is 10.34.
Suven Pharma - Quaterly Results
Publish Date: 08/11/2022
The sales slipped to Rs. 2784.02 millions for the September 2022 quarter as against Rs. 3009.88 millions during the year-ago period.Profit after Tax for the quarter ended September 2022 saw a decline of -31.49% from Rs. 1151.98 millions to Rs. 789.22 millions.Operating Profit reported a sharp decline to 1170.32 millions from 1601.10 millions in the corresponding previous quarter.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 2784.02 | 3009.88 | -7.50 | 6172.01 | 5647.89 | 9.28 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 103.89 | 383.35 | -72.90 | 212.87 | 441.18 | -51.75 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1170.32 | 1601.10 | -26.91 | 2826.69 | 2805.09 | 0.77 | 7677.76 | 4547.59 | 68.83 |
| Interest | 2.90 | 11.75 | -75.32 | 17.23 | 33.01 | -47.80 | 62.31 | 91.44 | -31.86 |
| PBDT | 1167.42 | 1589.35 | -26.55 | 2809.46 | 2772.08 | 1.35 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 107.56 | 91.77 | 17.21 | 213.04 | 181.70 | 17.25 | 390.97 | 316.36 | 23.58 |
| PBT | 1059.86 | 1497.58 | -29.23 | 2596.42 | 2590.38 | 0.23 | 7224.48 | 4139.79 | 74.51 |
| TAX | 270.64 | 345.60 | -21.69 | 666.69 | 623.99 | 6.84 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 14.39 | 17.80 | -19.16 | 21.63 | 24.56 | -11.93 | 67.19 | 36.17 | 85.76 |
| PAT | 789.22 | 1151.98 | -31.49 | 1929.73 | 1966.39 | -1.86 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 42.04 | 53.19 | -20.98 | 45.80 | 49.67 | -7.79 | 58.16 | 45.04 | 29.12 |
Suven Pharma - Quaterly Results
Publish Date: 08/11/2022
The sales for the September 2022 quarter moved down to Rs. 2784.02 millions as compared to Rs. 3009.88 millions during the year-ago period.The Net Profit of the company slipped to Rs. 789.22 millions from Rs. 1151.98 millions, a decline of -31.49% on QoQ basis.A decline of 1170.32 millions was observed in the OP in the quarter ended September 2022 from 1601.10 millions on QoQ basis.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 2784.02 | 3009.88 | -7.50 | 6172.01 | 5647.89 | 9.28 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 103.89 | 383.35 | -72.90 | 212.87 | 441.18 | -51.75 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1170.32 | 1601.10 | -26.91 | 2826.69 | 2805.09 | 0.77 | 7677.76 | 4547.59 | 68.83 |
| Interest | 2.90 | 11.75 | -75.32 | 17.23 | 33.01 | -47.80 | 62.31 | 91.44 | -31.86 |
| PBDT | 1167.42 | 1589.35 | -26.55 | 2809.46 | 2772.08 | 1.35 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 107.56 | 91.77 | 17.21 | 213.04 | 181.70 | 17.25 | 390.97 | 316.36 | 23.58 |
| PBT | 1059.86 | 1497.58 | -29.23 | 2596.42 | 2590.38 | 0.23 | 7224.48 | 4139.79 | 74.51 |
| TAX | 270.64 | 345.60 | -21.69 | 666.69 | 623.99 | 6.84 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 14.39 | 17.80 | -19.16 | 21.63 | 24.56 | -11.93 | 67.19 | 36.17 | 85.76 |
| PAT | 789.22 | 1151.98 | -31.49 | 1929.73 | 1966.39 | -1.86 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 42.04 | 53.19 | -20.98 | 45.80 | 49.67 | -7.79 | 58.16 | 45.04 | 29.12 |
Suven Pharma - Quaterly Results
Publish Date: 08/11/2022
The sales for the September 2022 quarter moved down to Rs. 2784.02 millions as compared to Rs. 3009.88 millions during the year-ago period.The Net Profit of the company slipped to Rs. 789.22 millions from Rs. 1151.98 millions, a decline of -31.49% on QoQ basis.A decline of 1170.32 millions was observed in the OP in the quarter ended September 2022 from 1601.10 millions on QoQ basis.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 2784.02 | 3009.88 | -7.50 | 6172.01 | 5647.89 | 9.28 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 103.89 | 383.35 | -72.90 | 212.87 | 441.18 | -51.75 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1170.32 | 1601.10 | -26.91 | 2826.69 | 2805.09 | 0.77 | 7677.76 | 4547.59 | 68.83 |
| Interest | 2.90 | 11.75 | -75.32 | 17.23 | 33.01 | -47.80 | 62.31 | 91.44 | -31.86 |
| PBDT | 1167.42 | 1589.35 | -26.55 | 2809.46 | 2772.08 | 1.35 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 107.56 | 91.77 | 17.21 | 213.04 | 181.70 | 17.25 | 390.97 | 316.36 | 23.58 |
| PBT | 1059.86 | 1497.58 | -29.23 | 2596.42 | 2590.38 | 0.23 | 7224.48 | 4139.79 | 74.51 |
| TAX | 270.64 | 345.60 | -21.69 | 666.69 | 623.99 | 6.84 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 14.39 | 17.80 | -19.16 | 21.63 | 24.56 | -11.93 | 67.19 | 36.17 | 85.76 |
| PAT | 789.22 | 1151.98 | -31.49 | 1929.73 | 1966.39 | -1.86 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 42.04 | 53.19 | -20.98 | 45.80 | 49.67 | -7.79 | 58.16 | 45.04 | 29.12 |
Suven Pharma - Quaterly Results
Publish Date: 06/02/2023
The sales is pegged at Rs. 3484.89 millions for the December 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 3915.85 millions during the year-ago period.Net profit declined -20.09% to Rs. 1094.66 millions from Rs. 1369.94 millions.Operating Profit reported a sharp decline to 1595.77 millions from 1953.02 millions in the corresponding previous quarter.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 3484.89 | 3915.85 | -11.01 | 9656.90 | 9563.74 | 0.97 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 125.10 | 92.74 | 34.89 | 337.97 | 533.92 | -36.70 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1595.77 | 1953.02 | -18.29 | 4422.46 | 4758.11 | -7.05 | 7677.76 | 4547.59 | 68.83 |
| Interest | 13.79 | 7.42 | 85.85 | 31.02 | 40.43 | -23.27 | 62.31 | 91.44 | -31.86 |
| PBDT | 1581.98 | 1945.60 | -18.69 | 4391.44 | 4717.68 | -6.92 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 109.14 | 105.06 | 3.88 | 322.18 | 286.76 | 12.35 | 390.97 | 316.36 | 23.58 |
| PBT | 1472.84 | 1840.54 | -19.98 | 4069.26 | 4430.92 | -8.16 | 7224.48 | 4139.79 | 74.51 |
| TAX | 378.18 | 470.60 | -19.64 | 1044.87 | 1094.59 | -4.54 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 6.66 | 8.53 | -21.92 | 28.29 | 33.09 | -14.51 | 67.19 | 36.17 | 85.76 |
| PAT | 1094.66 | 1369.94 | -20.09 | 3024.39 | 3336.33 | -9.35 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 45.79 | 49.87 | -8.19 | 45.80 | 49.75 | -7.95 | 58.16 | 45.04 | 29.12 |
Suven Pharma - Quaterly Results
Publish Date: 06/02/2023
A decrease in the sales to Rs. 3484.89 millions was observed for the quarter ended December 2022. The sales stood at Rs. 3915.85 millions during the similar quarter previous year.The Net Profit of the company registered a slight decline of -20.09% to Rs. 1094.66 millions from Rs. 1369.94 millions.The company reported a degrowth in operating Profit to 1595.77 millions from 1953.02 millions.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 3484.89 | 3915.85 | -11.01 | 9656.90 | 9563.74 | 0.97 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 125.10 | 92.74 | 34.89 | 337.97 | 533.92 | -36.70 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1595.77 | 1953.02 | -18.29 | 4422.46 | 4758.11 | -7.05 | 7677.76 | 4547.59 | 68.83 |
| Interest | 13.79 | 7.42 | 85.85 | 31.02 | 40.43 | -23.27 | 62.31 | 91.44 | -31.86 |
| PBDT | 1581.98 | 1945.60 | -18.69 | 4391.44 | 4717.68 | -6.92 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 109.14 | 105.06 | 3.88 | 322.18 | 286.76 | 12.35 | 390.97 | 316.36 | 23.58 |
| PBT | 1472.84 | 1840.54 | -19.98 | 4069.26 | 4430.92 | -8.16 | 7224.48 | 4139.79 | 74.51 |
| TAX | 378.18 | 470.60 | -19.64 | 1044.87 | 1094.59 | -4.54 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 6.66 | 8.53 | -21.92 | 28.29 | 33.09 | -14.51 | 67.19 | 36.17 | 85.76 |
| PAT | 1094.66 | 1369.94 | -20.09 | 3024.39 | 3336.33 | -9.35 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 45.79 | 49.87 | -8.19 | 45.80 | 49.75 | -7.95 | 58.16 | 45.04 | 29.12 |
Suven Pharma - Quaterly Results
Publish Date: 06/02/2023
A decrease in the sales to Rs. 3484.89 millions was observed for the quarter ended December 2022. The sales stood at Rs. 3915.85 millions during the similar quarter previous year.The Net Profit of the company registered a slight decline of -20.09% to Rs. 1094.66 millions from Rs. 1369.94 millions.The company reported a degrowth in operating Profit to 1595.77 millions from 1953.02 millions.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 3484.89 | 3915.85 | -11.01 | 9656.90 | 9563.74 | 0.97 | 13202.22 | 10097.19 | 30.75 |
| Other Income | 125.10 | 92.74 | 34.89 | 337.97 | 533.92 | -36.70 | 1877.88 | 142.37 | 1219.01 |
| PBIDT | 1595.77 | 1953.02 | -18.29 | 4422.46 | 4758.11 | -7.05 | 7677.76 | 4547.59 | 68.83 |
| Interest | 13.79 | 7.42 | 85.85 | 31.02 | 40.43 | -23.27 | 62.31 | 91.44 | -31.86 |
| PBDT | 1581.98 | 1945.60 | -18.69 | 4391.44 | 4717.68 | -6.92 | 7615.45 | 4456.15 | 70.90 |
| Depreciation | 109.14 | 105.06 | 3.88 | 322.18 | 286.76 | 12.35 | 390.97 | 316.36 | 23.58 |
| PBT | 1472.84 | 1840.54 | -19.98 | 4069.26 | 4430.92 | -8.16 | 7224.48 | 4139.79 | 74.51 |
| TAX | 378.18 | 470.60 | -19.64 | 1044.87 | 1094.59 | -4.54 | 1643.49 | 1053.32 | 56.03 |
| Deferred Tax | 6.66 | 8.53 | -21.92 | 28.29 | 33.09 | -14.51 | 67.19 | 36.17 | 85.76 |
| PAT | 1094.66 | 1369.94 | -20.09 | 3024.39 | 3336.33 | -9.35 | 5580.99 | 3086.47 | 80.82 |
| Equity | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 | 254.57 | 254.57 | 0.00 |
| PBIDTM(%) | 45.79 | 49.87 | -8.19 | 45.80 | 49.75 | -7.95 | 58.16 | 45.04 | 29.12 |
Suven Pharmaceuticals informs about disclosure
Publish Date: 03/11/2022
Suven Pharmaceuticals has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs.
The above information is a part of company’s filings submitted to BSE.
Suven Pharmaceuticals informs about press release
Publish Date: 26/12/2022
Suven Pharmaceuticals has informed that the Board of Directors of the Company have been informed by its Promoter, Jasti Property and Equity Holdings (in its capacity as sole trustee of Jasti Family Trust), that they have executed a Share Purchase Agreement with Berhyanda, a Cyprus based company on December 26, 2022. The company has attached Press Release of the acquirer. This intimation is also being uploaded on the Company’s website at www.suvenpharm.com.
The above information is a part of company’s filings submitted to BSE.
Suven Pharmaceuticals informs about open offer
Publish Date: 26/12/2022
Suven Pharmaceuticals has informed that, Kotak Mahindra Capital Company (‘Manager to the Open Offer’) has submitted to BSE a copy of Public Announcement for the attention of the public shareholders of Suven Pharmaceuticals (‘Target Company’) under Regulation 3(1) and Regulation 4 read with Regulations 13, 14 and 15(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto.
The above information is a part of company’s filings submitted to BSE.
Suven Pharmaceuticals informs about board meeting
Publish Date: 30/01/2023
Suven Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on Monday, the February 6, 2023 at 11:30 am at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No. 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2022 and related matters. Further informed that, Trading Window for dealing in the securities of the company is already closed from 01st January, 2023 as per PIT Code of the Company. Trading window will be opened from 10th February, 2023.
The above information is a part of company’s filings submitted to BSE.
Suven Pharmaceuticals informs about conference call for investors
Publish Date: 31/01/2023
Suven Pharmaceuticals has informed that it enclosed an invitation for conducting the conference call for investors on Tuesday, February 7, 2023 at 12:00 Noon IST to discuss the Un-Audited Financial Results for the Q3 & 9M FY23, to be declared on February 6, 2023.
The above information is a part of company’s filings submitted to BSE.
Board Meeting
Publish Date: 06/02/2023
Quarterly Results
Ex Dividend
Publish Date: 09/09/2022
Ex Dividend
Publish Date: 09/09/2022
Interim Dividend
Board Meeting
Publish Date: 02/09/2022
Interim Dividend
Board Meeting
Publish Date: 08/08/2022
Quarterly Results
Ex Dividend
Publish Date: 13/05/2022
Rs.1.0000 per share(100%)Special Dividend
Ex Dividend
Publish Date: 13/05/2022
Interim Dividend
Board Meeting
Publish Date: 09/05/2022
Interim Dividend & Audited Results
Ex Dividend
Publish Date: 15/02/2022
Rs.2.0000 per share (200%) One Time Special Dividend
Ex Dividend
Publish Date: 15/02/2022
Interim Dividend
Board Meeting
Publish Date: 08/02/2022
Special Dividend
Board Meeting
Publish Date: 06/11/2021
Quarterly Results
Suven Pharmaceuticals’ arm gets EIR from USFDA for pre-approval inspection
Publish Date: 04/10/2022
The pre- approval inspection was conducted during July 25, 2022 through July 29, 2022
Suven Pharmaceuticals’ wholly owned subsidiary -- Casper Parma has received EIR from US Food and Drug Administration (USFDA) for its pre-approval inspection (PAI). The pre- approval inspection was conducted during July 25, 2022 through July 29, 2022. The inspection concluded with no observation (FDA-483) issued. Pre-Approval Inspections covering of three applications: NDA 016084, ANDA 217020 and ANDA 217030.
Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family
Publish Date: 26/12/2022
The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven’s public shareholders
Advent International (Advent) has entered into a definitive agreement to acquire significant stake in Suven Pharmaceuticals ( Suven) from the Jasti family, subject to regulatory approvals and conditions. Post the completion of this landmark acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences (Cohance) with Suven, to build a leading end-to-end CDMO and merchant API player servicing the pharma and specialty chemical markets.
The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven’s public shareholders and will be subject to regulatory approvals and other customary approvals. As part of the transaction, Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Open A Free Demat Account
Sign Up
